Curis (NASDAQ:CRIS) Releases Earnings Results, Beats Expectations By $0.11 EPS

Curis (NASDAQ:CRIS) announced its earnings results on Monday. The biotechnology company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.11, Zacks reports. The business had revenue of $2.70 million during the quarter, compared to analysts’ expectations of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%.

Curis Stock Down 30.5 %

Shares of CRIS stock traded down $0.64 during trading hours on Tuesday, reaching $1.46. 289,004 shares of the stock traded hands, compared to its average volume of 93,750. The firm has a market capitalization of $12.36 million, a PE ratio of -0.19 and a beta of 3.49. Curis has a 1-year low of $1.40 and a 1-year high of $17.49. The business has a fifty day moving average price of $3.01 and a 200 day moving average price of $3.86.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reduced their target price on shares of Curis from $20.00 to $16.00 and set a “buy” rating for the company in a report on Monday. StockNews.com initiated coverage on Curis in a research note on Saturday. They set a “hold” rating for the company.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.